Do analysts recommend BIOG or GROW?

Molten Ventures has a consensus target price of GBX 638.67, suggesting a potential downside of 5.31%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts clearly believe Molten Ventures is more favorable than The Biotech Growth Trust. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score The Biotech Growth Trust 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Molten Ventures 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer BIOG or FCSS?

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.53 beat Fidelity China Special's score of 1.24 indicating that The Biotech Growth Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment The Biotech Growth Trust 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fidelity China Special 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOG or USA?

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.53 beat Baillie Gifford US Growth's score of 0.05 indicating that The Biotech Growth Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment The Biotech Growth Trust 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Baillie Gifford US Growth 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

The Biotech Growth Trust (BIOG) Competitors

GBX 1,482 -18.00 (-1.20%)

As of 12:31 PM Eastern

Compare

BIOG vs. GROW, FCSS, GSS, SDP, and USA

Should you buy The Biotech Growth Trust stock or one of its competitors? The Biotech Growth Trust's main competitors and comparable companies include Molten Ventures (GROW), Fidelity China Special (FCSS), Genesis Emerging Markets Fund (GSS), Schroder Investment Trust - Schroder AsiaPacific Fund (SDP), and Baillie Gifford US Growth (USA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does The Biotech Growth Trust compare to Molten Ventures?

The Biotech Growth Trust (LON:BIOG) and Molten Ventures (LON:GROW) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Molten Ventures. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Molten Ventures. The Biotech Growth Trust's average media sentiment score of 1.53 beat Molten Ventures' score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Overall Sentiment
The Biotech Growth Trust	Very Positive
Molten Ventures	Neutral

The Biotech Growth Trust has a beta of 0.577, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Molten Ventures has a beta of 1.9564402, meaning that its stock price is 96% more volatile than the broader market.

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 40.5% of Molten Ventures shares are held by institutional investors. 1.5% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 1.6% of Molten Ventures shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Molten Ventures has a consensus target price of GBX 638.67, suggesting a potential downside of 5.31%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts clearly believe Molten Ventures is more favorable than The Biotech Growth Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Biotech Growth Trust	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Molten Ventures	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

The Biotech Growth Trust has a net margin of 96.47% compared to Molten Ventures' net margin of 75.09%. The Biotech Growth Trust's return on equity of 48.26% beat Molten Ventures' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Molten Ventures	75.09%	9.21%	-3.46%

The Biotech Growth Trust has higher earnings, but lower revenue than Molten Ventures. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.10	£83.83M	£558.00	2.66
Molten Ventures	£148M	7.87	-£33.58M	£69.00	9.78

Summary

Molten Ventures beats The Biotech Growth Trust on 9 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Fidelity China Special?

The Biotech Growth Trust (LON:BIOG) and Fidelity China Special (LON:FCSS) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 7.8% of Fidelity China Special shares are owned by institutional investors. 1.5% of The Biotech Growth Trust shares are owned by company insiders. Comparatively, 0.1% of Fidelity China Special shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

The Biotech Growth Trust has a net margin of 96.47% compared to Fidelity China Special's net margin of 81.41%. The Biotech Growth Trust's return on equity of 48.26% beat Fidelity China Special's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Fidelity China Special	81.41%	9.12%	N/A

The Biotech Growth Trust has a beta of 0.577, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Fidelity China Special has a beta of 0.919, suggesting that its share price is 8% less volatile than the broader market.

Fidelity China Special has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Fidelity China Special, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.10	£83.83M	£558.00	2.66
Fidelity China Special	£146.54M	7.68	£997.06M	£29.75	8.32

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.53 beat Fidelity China Special's score of 1.24 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Biotech Growth Trust	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fidelity China Special	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

The Biotech Growth Trust beats Fidelity China Special on 7 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Genesis Emerging Markets Fund?

The Biotech Growth Trust (LON:BIOG) and Genesis Emerging Markets Fund (LON:GSS) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

The Biotech Growth Trust has higher earnings, but lower revenue than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.10	£83.83M	£558.00	2.66
Genesis Emerging Markets Fund	£250.40M	0.00	N/A	£140.70	N/A

The Biotech Growth Trust has a net margin of 96.47% compared to Genesis Emerging Markets Fund's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat Genesis Emerging Markets Fund's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Genesis Emerging Markets Fund	N/A	N/A	N/A

10.5% of The Biotech Growth Trust shares are owned by institutional investors. 1.5% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Genesis Emerging Markets Fund. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Genesis Emerging Markets Fund. The Biotech Growth Trust's average media sentiment score of 1.53 beat Genesis Emerging Markets Fund's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Overall Sentiment
The Biotech Growth Trust	Very Positive
Genesis Emerging Markets Fund	Neutral

Summary

The Biotech Growth Trust beats Genesis Emerging Markets Fund on 8 of the 10 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Schroder Investment Trust - Schroder AsiaPacific Fund?

The Biotech Growth Trust (LON:BIOG) and Schroder Investment Trust - Schroder AsiaPacific Fund (LON:SDP) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

The Biotech Growth Trust has a beta of 0.577, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Schroder Investment Trust - Schroder AsiaPacific Fund has a beta of 0.958, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Schroder Investment Trust - Schroder AsiaPacific Fund had 1 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 2 mentions for Schroder Investment Trust - Schroder AsiaPacific Fund and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.53 beat Schroder Investment Trust - Schroder AsiaPacific Fund's score of 0.32 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Biotech Growth Trust	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Schroder Investment Trust - Schroder AsiaPacific Fund	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 17.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are held by institutional investors. 1.5% of The Biotech Growth Trust shares are held by insiders. Comparatively, 0.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Schroder Investment Trust - Schroder AsiaPacific Fund has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Schroder Investment Trust - Schroder AsiaPacific Fund, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.10	£83.83M	£558.00	2.66
Schroder Investment Trust - Schroder AsiaPacific Fund	£191.10M	5.57	£121.21M	£135.64	6.30

The Biotech Growth Trust has a net margin of 96.47% compared to Schroder Investment Trust - Schroder AsiaPacific Fund's net margin of 95.12%. The Biotech Growth Trust's return on equity of 48.26% beat Schroder Investment Trust - Schroder AsiaPacific Fund's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Schroder Investment Trust - Schroder AsiaPacific Fund	95.12%	20.01%	-1.73%

Summary

Schroder Investment Trust - Schroder AsiaPacific Fund beats The Biotech Growth Trust on 7 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Baillie Gifford US Growth?

The Biotech Growth Trust (LON:BIOG) and Baillie Gifford US Growth (LON:USA) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

The Biotech Growth Trust has a beta of 0.577, indicating that its share price is 42% less volatile than the broader market. Comparatively, Baillie Gifford US Growth has a beta of 0.618, indicating that its share price is 38% less volatile than the broader market.

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.53 beat Baillie Gifford US Growth's score of 0.05 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Biotech Growth Trust	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Baillie Gifford US Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Baillie Gifford US Growth has lower revenue, but higher earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Baillie Gifford US Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.10	£83.83M	£558.00	2.66
Baillie Gifford US Growth	£58.05M	18.31	£84.35M	£19.81	19.38

Baillie Gifford US Growth has a net margin of 96.49% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat Baillie Gifford US Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Baillie Gifford US Growth	96.49%	25.27%	N/A

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 5.8% of Baillie Gifford US Growth shares are held by institutional investors. 1.5% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 0.2% of Baillie Gifford US Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

The Biotech Growth Trust beats Baillie Gifford US Growth on 7 of the 12 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOG vs. The Competition

Export

Metric	The Biotech Growth Trust	Capital Markets Industry	Finance Sector	LON Exchange
Market Cap	£281.37M	£5.15B	£13.32B	£2.80B
Dividend Yield	N/A	7.55%	6.03%	6.18%
P/E Ratio	2.66	29.40	24.49	366.17
Price / Sales	2.10	1,256.39	505.88	89,425.29
Price / Cash	87.74	47.77	47.45	27.89
Price / Book	1.38	3.49	2.70	6.83
Net Income	£83.83M	£417.69M	£1.32B	£5.89B
7 Day Performance	-4.26%	-0.73%	-1.04%	-0.75%
1 Month Performance	-12.41%	5.22%	1.00%	16.84%
1 Year Performance	45.94%	3.31%	8.15%	16.40%

The Biotech Growth Trust Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOG The Biotech Growth Trust	N/A	GBX 1,482 -1.2%	N/A	+46.3%	£281.37M	£133.86M	2.66	N/A	Positive News
GROW Molten Ventures	0.7693 of 5 stars	GBX 675 +0.7%	GBX 638.67 -5.4%	+76.1%	£1.17B	£148M	9.78	20
FCSS Fidelity China Special	N/A	GBX 252.16 -0.5%	N/A	-23.2%	£1.15B	£146.54M	8.48	N/A	News Coverage Positive News
GSS Genesis Emerging Markets Fund	N/A	N/A	N/A	N/A	£1.06B	£250.40M	6.18	1,626	Gap Down
SDP Schroder Investment Trust - Schroder AsiaPacific Fund	N/A	GBX 847.70 -1.3%	N/A	+31.5%	£1.05B	£191.10M	6.25	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The Biotech Growth Trust (BIOG) Competitors

BIOG vs. GROW, FCSS, GSS, SDP, and USA

How does The Biotech Growth Trust compare to Molten Ventures?

Summary

How does The Biotech Growth Trust compare to Fidelity China Special?

Summary

How does The Biotech Growth Trust compare to Genesis Emerging Markets Fund?

Summary

How does The Biotech Growth Trust compare to Schroder Investment Trust - Schroder AsiaPacific Fund?

Summary

How does The Biotech Growth Trust compare to Baillie Gifford US Growth?

Summary

Media Sentiment Over Time

BIOG vs. The Competition

The Biotech Growth Trust Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

The Biotech Growth Trust (BIOG) Competitors

BIOG vs. GROW, FCSS, GSS, SDP, and USA

How does The Biotech Growth Trust compare to Molten Ventures?

Does the media favor BIOG or GROW?

Which has more volatility and risk, BIOG or GROW?

Do insiders and institutionals have more ownership in BIOG or GROW?

Do analysts recommend BIOG or GROW?

Is BIOG or GROW more profitable?

Which has higher valuation & earnings, BIOG or GROW?

Summary

How does The Biotech Growth Trust compare to Fidelity China Special?

Do institutionals & insiders believe in BIOG or FCSS?

Is BIOG or FCSS more profitable?

Which has more volatility & risk, BIOG or FCSS?

Which has preferable earnings & valuation, BIOG or FCSS?

Does the media prefer BIOG or FCSS?

Summary

How does The Biotech Growth Trust compare to Genesis Emerging Markets Fund?

Which has stronger valuation and earnings, BIOG or GSS?

Is BIOG or GSS more profitable?

Do institutionals and insiders have more ownership in BIOG or GSS?

Does the media favor BIOG or GSS?

Summary

How does The Biotech Growth Trust compare to Schroder Investment Trust - Schroder AsiaPacific Fund?

Which has more risk & volatility, BIOG or SDP?

Does the media refer more to BIOG or SDP?

Do insiders & institutionals believe in BIOG or SDP?

Which has higher earnings & valuation, BIOG or SDP?

Is BIOG or SDP more profitable?

Summary

How does The Biotech Growth Trust compare to Baillie Gifford US Growth?

Which has more volatility and risk, BIOG or USA?

Does the media prefer BIOG or USA?

Which has preferable valuation & earnings, BIOG or USA?

Is BIOG or USA more profitable?

Do insiders and institutionals believe in BIOG or USA?

Summary

Media Sentiment Over Time

BIOG vs. The Competition

The Biotech Growth Trust Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools